Prevention of chloroquine-induced electroretinographic damage by a new platelet-activating factor antagonist, BN 50730. 1993

M Doly, and J Cluzel, and M Millerin, and B Bonhomme, and P Braquet
Laboratoire de Biophysique, INSERM U71, Facultés de Médecine et de Pharmacie, Clermont-Ferrand, France.

Chloroquine retinopathy is a severe toxic retinal impairment which may result in loss of vision by alterations of the retinal pigment epithelium and photoreceptors. Currently, there is no specific treatment for this retinopathy. Platelet-activating factor (PAF) is known to modulate retinal function and is one of the major immunomediators of the retina. In order to test the possible involvement of PAF in chloroquine-induced retinopathy and the effectiveness of PAF antagonists in the prevention of this condition, we investigated the effects of BN 50730, a specific PAF antagonist, on the electroretinogram (ERG) of the isolated rat retina exposed to chloroquine. When retinas from normal rats were perfused with chloroquine (10(-6) M), a marked and rapid decrease in b-wave amplitude was observed. In contrast, chloroquine had no effect on the b-wave of the retina isolated from animals pretreated with the PAF antagonist BN 50730 (30 mg/kg/day, i.p., for 5 days). The results obtained indicate that (i) chloroquine is a toxic drug for retinal function, (ii) PAF plays a key role in the mediation of chloroquine retinopathy and (iii) PAF antagonists may constitute valuable agents for the treatment of this retinal impairment.

UI MeSH Term Description Entries
D010972 Platelet Activating Factor A phospholipid derivative formed by PLATELETS; BASOPHILS; NEUTROPHILS; MONOCYTES; and MACROPHAGES. It is a potent platelet aggregating agent and inducer of systemic anaphylactic symptoms, including HYPOTENSION; THROMBOCYTOPENIA; NEUTROPENIA; and BRONCHOCONSTRICTION. AGEPC,Acetyl Glyceryl Ether Phosphorylcholine,PAF-Acether,Phosphorylcholine, Acetyl Glyceryl Ether,1-Alkyl-2-acetyl-sn-glycerophosphocholine,Platelet Aggregating Factor,Platelet Aggregation Enhancing Factor,Platelet-Activating Substance,Thrombocyte Aggregating Activity,1 Alkyl 2 acetyl sn glycerophosphocholine,Aggregating Factor, Platelet,Factor, Platelet Activating,PAF Acether,Platelet Activating Substance
D012160 Retina The ten-layered nervous tissue membrane of the eye. It is continuous with the OPTIC NERVE and receives images of external objects and transmits visual impulses to the brain. Its outer surface is in contact with the CHOROID and the inner surface with the VITREOUS BODY. The outer-most layer is pigmented, whereas the inner nine layers are transparent. Ora Serrata
D012164 Retinal Diseases Diseases involving the RETINA. Disease, Retinal,Diseases, Retinal,Retinal Disease
D002738 Chloroquine The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. Aralen,Arechine,Arequin,Chingamin,Chlorochin,Chloroquine Sulfate,Chloroquine Sulphate,Khingamin,Nivaquine,Sulfate, Chloroquine,Sulphate, Chloroquine
D003623 Dark Adaptation Adjustment of the eyes under conditions of low light. The sensitivity of the eye to light is increased during dark adaptation. Scotopic Adaptation,Adaptation, Dark,Adaptation, Scotopic
D004596 Electroretinography Recording of electric potentials in the retina after stimulation by light. Electroretinographies
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001381 Azepines Seven membered heterocyclic rings containing a NITROGEN atom. Hexamethyleneimines
D013777 Tetrazoles
D014230 Triazoles Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3. Triazole

Related Publications

M Doly, and J Cluzel, and M Millerin, and B Bonhomme, and P Braquet
February 1995, Annals of the rheumatic diseases,
M Doly, and J Cluzel, and M Millerin, and B Bonhomme, and P Braquet
September 1995, The Journal of rheumatology,
M Doly, and J Cluzel, and M Millerin, and B Bonhomme, and P Braquet
June 2001, Pediatric research,
M Doly, and J Cluzel, and M Millerin, and B Bonhomme, and P Braquet
June 1995, Pharmacology & toxicology,
M Doly, and J Cluzel, and M Millerin, and B Bonhomme, and P Braquet
April 1990, The British journal of dermatology,
M Doly, and J Cluzel, and M Millerin, and B Bonhomme, and P Braquet
May 1986, European journal of pharmacology,
M Doly, and J Cluzel, and M Millerin, and B Bonhomme, and P Braquet
April 1993, Molecular immunology,
M Doly, and J Cluzel, and M Millerin, and B Bonhomme, and P Braquet
September 1997, Journal of neurochemistry,
M Doly, and J Cluzel, and M Millerin, and B Bonhomme, and P Braquet
May 1988, Prostaglandins,
M Doly, and J Cluzel, and M Millerin, and B Bonhomme, and P Braquet
September 1990, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!